Skye Bioscience, Inc. · NASDAQ:SKYE
Skye Bioscience — Nemus Bioscience — BIO CEO 2018
29 slides from Skye Bioscience's conference presentation, Feb 13, 2018
Slide 1: NEMUS Bioscience
NEMUS Bioscience OTCQB: NMUS BIO CEO February 13, 2018
Slide 2: Legal Disclaimer
Legal Disclaimer apNeEMUS —_—_—_—_—_——____.:.:.?.?.?.?.?. ow This presentation contains “forward-looking statements’, including statements regarding Nemus Bioscience, Inc. and its subsidiaries, within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform ‘Act of 199
Slide 3: Company Overview
Company Overview rm PNEMUS | NEMUS Bioscience is a publicly traded, life-science biotech company, focused on developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need $0.39/share iieccteaaads 52-week high/low: $0.48/$0.10 ‘Market
Slide 4: Nemus and Emerald Health
emerald Gx. Nemus and Emerald Health S@NEMUS | Nemus Secures Emerald Health Sciences as Strategic Majority Investor to help Advance Clinical Development of Novel Cannabinoid-based Therapeutics + Emerald Health Sciences is an operating company focused on the medicinal potential of cannabis and cannab
Slide 5: NEMUS Value Proposition
NEMUS Value Propo: Disrupting the cannabinoid therapeutic space Developing Biosynthetic innabinoids Targeting Unmet Needs in Multi- Billion Dollar Global Markets Sole Development & Commercialization Partner with UM Proprietary Pipeline with Global Patent Footprint ion: * Currently, the only cannabin
Slide 6: Exclusive strategic relationship with the University of Mississippi
Exclusive strategic relationship with the University of Mi: provides access to a diverse cannabinoid patent estate “THE UNIVERSITY OF MISSISSIPPI en 16) 20 (G01) UK G he University are currently eng n hybrid synthetic cannabinoi
Slide 7: Innovative Cannabinoid Formulations
Innovative Cannabinoid Formulations Designed for Improved Drug Delivery All NEMUS licensed delivery options optimize our prodrug cannabinoid technology by enhancing bioavailability by avoiding first-pass liver metabolism and offering more predictable pharmacokinetics Ocular Delivery Transmucosal Del
Slide 8: Nemus Cannabinoid Development Portfolio
Nemus Cannabinoid Development Portfolio Drug Candidate Target Indications Projected | Developmental Global stage Market Size Glaucoma NB1111 (Prodrug THC) $3+ Bt NB1222 (Prodrug THC) Chemotherapy-Induced $282 Nausea and Vomiting (CINV) NB2111 (Analogue CBD) Chemotherapy-Induced >$35 Be Research Peri
Slide 9: Nemus Ophthalmology Platform
Nemus Ophthalmology Platform “2NEMUS Prodrug of THC Analogue of CBD (NB1111) (NB2222) Posterior scanner RhoAgii ay Boy Compartment ei ia Anterior Compartment Macular degeneration (CBD; THC:cBD) opie Nae Diabetic retinopathy (cep) Sete Retinitis pigmentosa (orphan) (THC) Glaucoma (THC) Dry eye syndro
Slide 10: NB1111 For the Treatment of Glaucoma
@@NEMUS. NB1111 For the Treatment of Glaucoma
Slide 11: The Glaucoma Market
The Glaucoma Market Large Market High Unmet Medical Need Well Defined Regulatory Path Cannabinoids Demonstrate Efficacy & Neuroprotection Early Developmet M&A IMs; 2016 $3: billion globally and growing with aging populations $2.6 billion US market (35 MM Rx)* Glaucoma as a "Non-responder” market pre
Slide 12: Cannabinoid receptors in the eye
Cannabinoid receptors in the eye 8 CB, MRNA (% of 8m) s Reins Cliry Body tm a RR CB a on man a en St parle ge (B) Raa dilence of CB) ers aman 3 The lee of mRNA ine reins BSA" 246%) say bay (Gio 1h) an os 29 $000) we conga ty PCR CHT thaw mil hae nnd epeed ee Modulation of cannabinoid receptor tone a
Slide 13: THCVHS vs THC: CB receptor dynamics
THCVHS vs THC: CB receptor dynamics* PNEMUS | + Experiments have shown that THCVHS does not substantively bind CB receptors * The physiological effect comes from THC derived from the prodrug 81 Receptor Binding 82 Recep indng j sees ;: Bareieg i ene a, H seal Hi reer) i = Em ca TT TR Texas [aera | T
Slide 14: THCVHS vs pilocarpine and timolol achieves 45% reduction in IOP
THCVHS vs pilocarpine and timolol achieves 45% feduetion in lOp* PNEMUS | Percent Baseline OP Tne vas Tore THC 06% wy 300] “+ Timo leat ey ops (025 % ws) Plane ve rs(2 9) © 50 € S00 160 ike 2i0 0 m0 son 0 380 Freon 5. 101 pros obtained with THC-YALHS, tno maleate and plocsrpine eye dps (marketed in
Slide 15: THCVHS (prodrug) vs THC IOP reduction over time profile
THCVHS (prodrug) vs THC IOP reduction over time profile: Prodrug achieves significant decline in IOP using SLN (soli id nanoparticle) technology Data reveals the following: Le Pustiine pile + THCVHS in Tocrisolve exhibits IOP maximum decline of 47% + THCVHS in SLN exhibits IOP maximum decline of 35%
Slide 16: Superior reduction in IOP by THCVHS versus THC explained by tissue penetration
Superior reduction in IOP by THCVHS versus THC explained by enhanced tissue penetration into organs regulating IOP in rabbit _glaucoma model (testing to 180 minutes post-dose) sition at 180 min 1600 1400 NoTHC the study Fd 1200 = 1000 & 800 600 400 200 ‘THC-VHS-TOC THCSLN Formulations Aqueous Humor
Slide 17: Cannabinoids Shown to Be Neuroprotective in Multiple Animal Models
Cannabinoids Shown to Be Neuroprotective in Multiple Animal Models Assessing Integrity of the Optic Nerve @Nemus + Cannabinoid agonists have shown both Neuroprotective Etfect ofl-)4*Tetrahydrocannabinol Scclenl hypotefisive Hod neuroprotectiies ‘and Cannabidiol in Aspartate-Induced effect on retinal
Slide 18: NB1111 (Glaucoma/Ophthalmology)
NB1111 (Glaucoma/Ophthalmology) + Penetrates multiple chambers of the eye in test animals Julti- MeL SME «The proprietary formulation allows THC to be absorbed across membranes that eMC eWtteWelaN) are normally barriers to absorption + Produces a 45% reduction in Intra-Ocular Pressure (IOP) in glauc
Slide 19: Analogue of CBD: NB2222 Dry Eye Syndrome
@@NEMUS. Analogue of CBD: NB2222 Dry Eye Syndrome
Slide 20: Global Dry Eye Syndrome Market Size and Forecast, 2015-2024
Global Dry Eye Syndrome Market Size and Forecast, 2015 - 2024 (USS Billion) @NEMUS Global Dry Eye Syndrome Market Size and Forecast, 2015 - 2024 (US$ Billion) pois -2001_ cen 69% (2088 2 | 2015 2016 2018 2019-2020» 2021. «2022, 2023-2024 Scurce: Variant Marat asech lot! Dy EyeSytome Watket Rept. 031
Slide 21: Treatment Categories for Dry Eye
Treatment Categories for Dry Eye* @NEMUS | Lubricants Nutrition Anti-inflammatory | Autologous serum’ Adjuncts agents lid margin disease management + Emulsions . Manual + Punctal occlusion Topical + Gels eyclosporine + Mechanical + Contact lenses + Ointments + Topical * Intense pulsed light * Enviro
Slide 22: NB2222: Assessing ocular permeation
NB2222: Assessing ocular permeation PNEMUS | STUDY PURPOSE + Cannabidiol (CBD) is one of the active components of the plant Cannabis sativa and has been studied in the management of neurological diseases, sleep disorders, and the management of pain. * CBD, by virtue of its anti-inflammatory properti
Slide 23: Tissue distribution of CBD derivatives
Tissue distribution of CBD derivatives @NEMUS | ‘Analog Conc (ng/g of tissue) & CBD Cone CBD Cone (ng/g of tue) ‘Analog Cone (ng/g of tissue) (ng/g of tissue) vs, Tissue Analyzed Formulation dosed 1000 | . = 680 3 cobs 000 1 CeD-DrvaL 5 ce-o-vHs 0 5 CBD-Mono-vHs © C8D-Mono-va i = ce 300 + Gos ie + c
Slide 24: NB2222 (CBD-Di-VHS) demonstrated best ocular bioavailability
NB2222 (CBVVHS) demonstrated best ocular bioavailability, cannabinoid activity & stability with slow conversion to CBD @Nemus 2 RESULTS In Vitro Studi CBD-Di-VHS showed a slow decline over six hours, but we did not observe bioconversion to CBD. The amino acid analogue, CBD-Di-Val retained analogue l
Slide 25: Nemus Revised Pipeline Timeline Relative to Goals (I)
Nemus Revised Pipeline Timeline Relative to Goals (1) @NEMUS | Lack of adequate financing in 2017 placed severe constraints on moving development forward across product silos The acquisition of Nemus by Emerald Health permitted a capital infusion to re-energize development programs The multi-billion
Slide 26: Nemus Revised Timeline Relative to Goals (II)
Nemus Revised Timeline Relative to Goals (II): Focus on synthesis and formulation @NEMUS Pre-clinTesting/ ‘Animal Modeling Clinical PoC Study Glaucoma 93-0418 NB1111 ee , + Canine nee Q1'18-Q2'18 CPOE ornate Q4’18-01'19 + Pre-IND Mtg Dry Eye Syndrome Q118-03'18 —-Q2’18-3'18«Q2’18-04'18 TBD NB2222 Pa
Slide 27: Management
Management Neus an. AAEC TTL BRIAN MURPHY, MD, MPH, MBA — Chief Executive Officer; Chief Medical Officer, Director Dr. Murphy has almost two decades of experience in drug development and evaluation, both from the academic and industry perspective. He most recently served as the CMO of Eiger Bioscien
Slide 28: Board of Directors and Strategic Advisors
Board of Directors and Strategic Advisors ” PNEMUS | ‘Avtar Dhillon, MD trecutive Charman of Emerald and ‘Strategic Advisor to Nemus MAHMOUD A. ELSOHLY, PHD Dr Ohlon i currently the Executive SelentieAdulsor ‘Chairman for Emerald Life Sciences and oer beneetarmemanshendenes: the former President and
Slide 29: Contact
Contact “2NEMUS & 2 Company: Investor Relations: Brian Murphy, MD, MPH, MBA Adam Holdsworth CEO - CMO PCG Advisory Group brian@nemusbio.com Tel: 646-862-4607 adamh@pcgadvisory.com <2=NEMUS BIOSCIENCE 600 Anton Blvd., Suite 1100 Costa Mesa, CA 92626 949-396-0330 hello@nemusbio.com www.nemusbioscience